Earnings call · Apr–Jun 2026
Ind-Swift Laboratories Ltd.
Apr–Jun 2026 saw operating income grow 21.16% to ₹186 crore & EBITDA margins expand 1,258 bps to 17.91%. CDMO partnerships with Viatris, Manx & Arrotex commercialized; export own-brands now 57.20% of sales, up from 48% from a year earlier.
The full notes: the guidance, numbers & KPIs, strategy, outlook, risks, what analysts asked.
Premium opens every call in full: the notes, the marked passages, search & topic jumps, for every company that files a transcript.
From the company
- Pardeep VermaVP-Corporate Affairs & Company Secretary
- Aryan Bhatia
- Gagan AggarwalChief Financial Officer
- Zaki Nasser
- Darshil Jhaveri
- Hemant Soni
- Amish Kanani
- Mohit Jangir
- Meet Katrodiya
- Gaurav Shukla
- Naitik Mohata
Topics in this call
Opening remarks
Pardeep VermaVP-Corporate Affairs & Company Secretary
Thank you, Ameya. Good afternoon, everyone, and a very warm welcome to the Q1 FY27 earnings call of Ind-Swift Laboratories Limited. On behalf of the Company, I thank you all for joining us today to discuss our operational and financial performance for the quarter ended 30th June, 2026. Let me take you through the business and financial updates for the quarter, following which we will open the floor for the question-and-answer session.
Q1 FY27 has been an excellent start to the year for Ind-Swift Laboratories, and I am pleased to share that the Company has delivered a strong quarter of performance, both operationally and financially, as we continue to build on our transformation from an API player into a focused, pure-play Finished Dosage Formulation, or FDF, manufacturer.
Read the whole call: 135 paragraphs, 1 analyst' questions with every answer, 8 marked passages.
Premium opens every call in full: the notes, the marked passages, search & topic jumps, for every company that files a transcript.
The transcript as the company filed it on BSE. Our own rules split it into speakers & sections; an unusual layout can trip them, so check the original PDF for anything important. Not a recommendation.